日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Poster Session I - A110 TRENDS IN SPENDING ON ADVANCED IBD THERAPIES PRESCRIBED BY GASTROENTEROLOGISTS IN MEDICARE

海报展示环节 I - A110 医疗保险中胃肠病学家开具的先进炎症性肠病 (IBD) 疗法支出趋势

Blauvelt, Andrew; Gooderham, Melinda; Griffiths, Christopher E M; Armstrong, April W; Zhu, Baojin; Burge, Russel; Gallo, Gaia; Guo, Jiaying; Garrelts, Alyssa; Lebwohl, Mark; Raber, M; Lu, C; Ma, C; Nasser, Y; Congly, S

The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis

临床阶段药物BTZ-043在小鼠结核病灶中聚集并有效对抗结核分枝杆菌

Andreas Römpp, Axel Treu #, Julia Kokesch-Himmelreich #, Franziska Marwitz #, Julia Dreisbach, Nadine Aboutara, Doris Hillemann, Moritz Garrelts, Paul J Converse, Sandeep Tyagi, Sina Gerbach, Luzia Gyr, Ann-Kathrin Lemm, Johanna Volz, Alexandra Hölscher, Leon Gröschel, Eva-Maria Stemp, Norbert Heinr

A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT

一项评估鲁索替尼治疗异基因造血干细胞移植后闭塞性细支气管炎综合征的II期多中心试验。

DeFilipp, Zachariah; Kim, Haesook T; Cheng, Guang-Shing; Hamilton, Betty K; Chhabra, Saurabh; Hamadani, Mehdi; Sandhu, Karamjeet S; Perez, Lia; Lee, Catherine J; Brennan, Timothy L; Garrelts, Cassandra; Brown, Bergin M; Gallagher, Kathleen; Newcomb, Richard A; El-Jawahri, Areej; Chen, Yi-Bin

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

伊克珠单抗(白细胞介素-17A 拮抗剂)与古塞库单抗(白细胞介素-23p19 抑制剂)治疗中重度斑块状银屑病患者,其身体各部位的反应速度和累积反应比较

Gooderham, Melinda; Vender, Ronald; Crowley, Jeffrey; Hong, H Chih-Ho; Feely, Meghan; Garrelts, Alyssa; See, Kyoungah; Konicek, Bruce; Green, Lawrence

Expanding Access to Patient Care in Community Pharmacies for Minor Illnesses in Washington State

扩大华盛顿州社区药房为轻微疾病患者提供医疗服务的渠道

Akers, Julie Marie; Miller, Jennifer C; Seignemartin, Brandy; MacLean, Linda Garrelts; Mandal, Bidisha; Kogan, Clark

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

致编辑的信:对 Fitzgerald T 等人的回应,《在美国使用 Guselkumab、Adalimumab、Secukinumab 或 Ixekizumab 长期控制银屑病》

Blauvelt, Andrew; Garrelts, Alyssa; Malatestinic, William; Birt, Julie; Zhu, Baojin; Feely, Meghan

Isotropic imaging across spatial scales with axially swept light-sheet microscopy.

利用轴向扫描光片显微镜实现跨空间尺度的各向同性成像

Dean Kevin M, Chakraborty Tonmoy, Daetwyler Stephan, Lin Jinlong, Garrelts Gerard, M'Saad Ons, Mekbib Hannahmariam T, Voigt Fabian F, Schaettin Martina, Stoeckli Esther T, Helmchen Fritjof, Bewersdorf Joerg, Fiolka Reto

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial

伊克珠单抗治疗中重度斑块状银屑病患儿长达 108 周的长期疗效和安全性:IXORA-PEDS 随机临床试验

Paller, Amy S; Seyger, Marieke M B; Magariños, Gabriel A; Pinter, Andreas; Cather, Jennifer C; Rodriguez-Capriles, Claudia; Zhu, Danting; Somani, Najwa; Garrelts, Alyssa; Papp, Kim A

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis

治疗所需人数网络荟萃分析比较生物制剂治疗中重度银屑病的疗效

Leonardi, Craig L; See, Kyoungah; Burge, Russel; Sun, Zhuoer; Zhang, Ying; Mallbris, Lotus; Garrelts, Alyssa; Warren, Richard B

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses

生物制剂治疗中重度斑块状银屑病的快速反应:一项基于贝叶斯和频率学派网络荟萃分析的综合研究

Warren, Richard B; See, Kyoungah; Burge, Russel; Zhang, Ying; Brnabic, Alan; Gallo, Gaia; Garrelts, Alyssa; Egeberg, Alexander